Introduction
============

Early in the HIV epidemic, gastrointestinal-related disease was a dominant presenting symptom complex. Jarry *et al.*[@R1] utilized histopathologic evaluations of the gut to demonstrate the profound immune depletion in gastrointestinal-associated lymphoid tissue (GALT) caused by HIV infection. HIV enteropathy became known as the syndrome of gastrointestinal complaints that persisted despite completion of appropriate therapy for any identified abnormalities [@R2; @R3]. It was believed to be due to HIV infection within the gastrointestinal mucosa, if not the enterocytes themselves, resulting in defects of mucosal function [@R4; @R5]. Despite the improvements in morbidity and mortality related to HIV infection [@R6], diarrhea and related gastrointestinal complaints remain in nearly 30% of patients on antiretroviral therapy (ART) [@R7; @R8].

GALT is recognized as a primary HIV target, irrespective of the mode of transmission, likely due to its constitutively high level of activation [@R9; @R10]. Within weeks of infection, human and nonhuman primate studies demonstrate infection of virtually all susceptible CD4^+^ T lymphocytes with HIV [@R11; @R12; @R13]. Despite effective ART, lymphocyte recovery in duodenal lamina propria lags far behind immune reconstitution in the peripheral blood compartment [@R14; @R15; @R16].

Depletion of lymphocytes in GALT leads to bacterial translocation, irrespective of the mechanism for cell loss [@R17; @R18]. Consequences of HIV-induced CD4^+^ T-cell depletion from GALT and microbial translocation as measured by plasma concentrations of lipopolysaccharide (LPS) and bacterial 16S ribosomal-RNA gene sequences (rDNA) include increased levels of proinflammatory cytokines and peripheral blood CD8^+^ T-cell subsets with an activated phenotype [@R19; @R20]. We have performed preliminary studies showing that the composition of the gut microbiota is correlated with both duodenal mucosal T-cell distribution and activation, as well as systemic immune activation in HIV patients both naïve or receiving ART [@R21].

Bovine serum immunoglobulin (SBI) is a specially formulated medical food that provides distinct nutritional support for the clinical dietary management of enteropathy under medical supervision. It is widely used in animal husbandry to reduce severe gastrointestinal manifestations of inflammation in young animals [@R22; @R23]. Animal model experiments of intestinal inflammation demonstrate that the immunoglobulins present in SBI neutralize LPS and other bacterial antigens and improve intestinal barrier function damaged by bacterial toxins [@R24; @R25; @R26; @R27]. This oral immunoglobulin undergoes reversible conformational changes under gastric pH and otherwise passes through the intestines unabsorbed. Available commercially, it has a long history of safety, including in children [@R28]. The hypothesis pursued in this clinical trial was that neutralization of proinflammatory bacterial antigen in the gut by SBI would lead to restoration of mucosal immunity and gastrointestinal function. We targeted study participants with a diagnosis of HIV enteropathy for this clinical trial as this population likely has an underlying disturbance in gut microbiota composition and altered gastrointestinal function as a feature of their immunopathology.

Methods
=======

Study design
------------

This open-label pilot study enrolled participants with the diagnosis of HIV enteropathy to receive 2.5 g of SBI (EnteraHealth, Akeny, Iowa, USA) twice daily for 8 weeks followed by a 4-week washout phase. HIV enteropathy was defined as chronic gastrointestinal symptoms including loose or watery stools and increased stool frequency (\>3/day) despite no identifiable, reversible cause. Participants with gastrointestinal symptoms after the washout phase were invited to enter into an extension period for an additional 9 months. Screening studies included stool samples for *Clostridium difficile* toxin, enteric pathogens, antigen testing for giardia, cryptosporidium, *Entamoeba histolytica*, *Helicobacter pylori*, and stains for ova and parasites, acid-fast bacilli, microsporidia, and isospora. Screening tests performed for food intolerance included endomysial antibodies to exclude gluten allergy and a period of lactose-free diet if indicated. ART-associated gastrointestinal intolerance was assessed either by a history of symptoms predating treatment initiation or persistence of symptoms despite a change in regimen. Continuation of stable, chronic antimotility agents was permitted with the provision that increases in doses were avoided. Study entry was delayed at least 4 weeks following antibiotic administration except for chronic Pneumocystis pneumonia prophylaxis. Participants underwent phlebotomy and stool submission at preentry and entry visits, at weeks 7 and 8 while receiving SBI, at week 12 after a 4-week washout, and then again at the end of 48 weeks for those participants who entered an extension study. Plasma and serum was available from a cohort of controls for comparison (*n* = 8). Analysis performed on the last sample available for a participant (end of treatment -- EOT) was week 8 or week 48. All participants signed an informed consent form approved by the UC Davis Institutional Review Board \[Clinical Trial Registry (Clinicaltrials.gov): NCT01313910\].

Gastrointestinal questionnaire and food diary
---------------------------------------------

A licensed dietician met with participants to assess food intolerance prior to enrollment and throughout the first 12 weeks to review a food diary. A steady diet was maintained in order to not confound observed clinical results. A validated gastrointestinal questionnaire, completed at each study visit, recorded daily stool frequency, stool consistency relying on a pictorial scale from 1 (normal, formed) to 6 (water, puddle-like), and gastrointestinal symptoms over the previous week [@R7]. The questions assessed symptoms including cramping, urgency, incontinence, and nocturnal bowel movements (possible score from 0 to 39 with normal \<4).

Gastrointestinal function assays: rhamnose/lactulose gut permeability and [d]{.smallcaps}-xylose absorption study
-----------------------------------------------------------------------------------------------------------------

The disaccharide gut permeability and [d]{.smallcaps}-xylose absorption study were performed in the week preceding study entry and after 7 weeks of SBI treatment. Participants consumed a syrup consisting of lactulose (5 g), [l]{.smallcaps}-rhamnose (1 g), and [d]{.smallcaps}-xylose (500 mg; BCM Specials Products, London, UK) on an empty stomach and collected all urine over the subsequent 4 h [@R29]. Urine disaccharide levels were measured in the laboratory of Dr Roy Sherwood [@R30]. Results are reported as the ratio of lactulose/[l]{.smallcaps}-rhamnose (normal \<0.05). Duodenal absorption function is reported as the amount of [d]{.smallcaps}-xylose collected in the urine over 4 h.

Upper endoscopy and tissue processing
-------------------------------------

Distal duodenum biopsies were obtained before and 8 weeks after initiating SBI. Tissue was either paraffin-embedded for routine histology and immunofluorescent antibody assay (IFA) or underwent digestion to single-cell suspension for polychromatic flow cytometry as previously described [@R31]. Peripheral blood mononuclear cells (PBMCs) were separated by Ficol-Hypaque and processed with the duodenal cells in identical fashion. Fluorescence-activated cell analysis was performed on a custom Becton-Dickinson LSRII cytometer and analyzed with FlowJo (TreeStar, Ashland, Oregon, USA).

For IFA analysis, the primary antibodies were polyclonal anti-CD3 rabbit serum (Dako Inc., Carpinteria, California, USA) and monoclonal anti-CD4 or CD8 mouse serum (Leica Microsystems, Buffalo Grove, Illinois, USA). Binding of CD3^+^ and CD4^+^ or CD8^+^ receptors was detected simultaneously using Alexafluor 488-labeled polyclonal goat antirabbit IgG and Alexafluor 568-labeled polyclonal goat antimouse IgG (both Molecular Probes, Eugene, Oregon, USA). Positive cells were counted by a single observer (Z.-M.M.) and presented as cells/mm^2^ of lamina propria or intraepithelial regions of duodenal mucosa [@R16; @R32; @R33] ([Fig. 1](#F1){ref-type="fig"}).

![Immunofluorescent antibody assay for T-lymphocyte populations in duodenal tissue.](aids-27-2207-g001){#F1}

Measurement of markers of microbial translocation, inflammatory cytokines, and fibrosis/collagen kinetics
---------------------------------------------------------------------------------------------------------

LPS was performed on serum obtained using pyrogen-free vacutainers as well as the standard serum separator and EDTA tubes for plasma with the Lonza LAL QCL-1000 kit (Lonza, Walkersville, Maryland, USA) according to the manufacturer\'s protocol in duplicate. Plasma LPS-binding protein (LBP) and bactericidal/permeability increasing protein (BPI; Uscn Life Science Inc., Missouri City, Texas, USA) were quantified by ELISA according to the manufacturer\'s protocol. Intestinal fatty acid binding protein (I-FABP; R&D Systems, Minneapolis, Minnesota, USA) was measured on serum diluted to 10% in sCD14 dilution buffer. Levels of proinflammatory (interleukin-1β \[IL-1β\], IL-6, tumor necrosis factor-α \[TNF-α\]), Th1 (interferon-γ \[IFN-γ\] and IL-12~p70~), Th2 (IL-4 and IL-10), and regulatory (IL-10) cytokines, chemokines (IL-8, and monocyte chemoattractant protein-1 \[MCP-1\], and biomarkers of collagen regulation (hyaluronic acid, transforming growth factor-β (TGF-β), matrix metalloproteinases-1 \[MMP-1\], MMP-9, tissue inhibitor of metalloproteinases-1 \[TIMP-1\], and TIMP-2) were all measured with multiplex enzyme-linked immunosorbent assay (ELISA)-based assays (MesoScale Discovery) except for hyaluronic acid (Corgenix, Broomfield, Colorado, USA).

Statistical approaches
----------------------

Nonparametric statistical methods were used throughout. Wilcoxon matched-pairs signed rank test was used for assessing changes between baseline and postintervention results and Mann--Whitney test was used to compare participants with normal control samples. The Spearman rank correlation coefficient was used to study correlations between parameters. All values are represented as the median (interquartile ranges) unless otherwise stated. As a pilot project designed to explore hypotheses for a larger placebo-controlled trial, no adjustments for multiple comparisons were included [@R34]. Analyses were performed with GraphPad Prism Software V5.0 (GraphPad Software, Inc., La Jolla, California, USA).

Results
=======

Participant demographics and clinical results
---------------------------------------------

All eight participants were men (five white, three African--American) with a median age of 44.5 years (38.8--47.8) and a peripheral blood CD4^+^ T-cell count of 372 cells/μl (193--459). All had been on ART for more than 1 year, including four on protease inhibitor-based, three on nonnucleoside reverse transcriptase inhibitor-based, and one on integrase inhibitor-based regimens with consistently undetectable viral loads. Two participants had CD4^+^ T-cell counts below 200 cells/μl and were on chronic trimethoprim-sulfamethoxazole prophylaxis therapy. The specimens from controls were used from a study with similar procedures including duodenal biopsies and stool and blood collection reported previously [@R16].

All tolerated SBI well with excellent compliance initially, as determined by pill counts, which declined during the extension period. Ironically, the only 'adverse event' reported by participants was perceived constipation when stool frequency fell to once a day in two of the participants. Three were either lost to follow-up or did not have a rebound of symptoms after the washout period and five completed the 48 weeks of observation on SBI. Thus, EOT analysis is at week 48 for five participants and week 8 for three participants. All participants experienced a consistent improvement in symptoms after 2--3 weeks, and all five participants on chronic antimotility agents at baseline only used them sporadically at the most. Bowel movements/day decreased from 5.8 (5.0--8.4) to 2 (2--3.8; *P* = 0.008), stool consistency \[1-formed to 6-watery\] decreased from 5.3 (5--6) to 3 (2.2--3.8; *P* = 0.008), and the gastrointestinal questionnaire score decreased from 17 (15.6--21.8) to 8.0 (3.5--11.9; *P* = 0.008) at week 8 compared to baseline ([Fig. 2](#F2){ref-type="fig"}). Participants who were experiencing urgency with episodes of soiling or night-time bowel movements reported complete resolution of such episodes. For those five who continued SBI to week 48, durable bowel movements/day, stool consistency, and questionnaire responses were reported at 2.0 (2.0--3.0), 2.5 (1.0--3.8), and 6.0 (2.0--12.8), respectively (all *P* = 0.062 compared to baseline).
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Intestinal permeability and absorptive function
-----------------------------------------------

Interestingly, as measured by the gold standard disaccharide absorption test, increased intestinal permeability was not observed in this cohort of participants. This is consistent with previous reports in HIV individuals without intestinal pathogens [@R30; @R35; @R36]. Gut permeability was normal before \[0.024% (0.0--0.048)\] and after \[0.032% (0.0--0.047)\] intervention ([Fig. 3](#F3){ref-type="fig"}a). However, [d]{.smallcaps}-xylose urinary excretion, reflecting distal duodenal absorption function, increased in seven of eight participants with an overall increase from a median of 33.8 mg (28.7--38.2) at baseline to 40.9 mg (19.8--44.4) at week 7 (*P* = 0.19; [Fig. 3](#F3){ref-type="fig"}b) [@R5].

![Intestinal permeability and absorptive function.](aids-27-2207-g003){#F3}

Histopathology and immunologic responses
----------------------------------------

Hematoxylin and eosin stain demonstrated mild reduction of the villus to crypt ratio of 2.1 (normal ≥ 3.0) overall. Focal tip apoptosis and nonspecific chronic inflammation were noted in four of eight without a trend related to SBI administration. Peripheral CD4^+^ T-cell counts were unchanged at 339 cells/μl (210--468) after 8 weeks and 348 cells/μl (225--397) after 48 weeks. Both CD4^+^ and CD8^+^ T cells with the activated phenotype remained unchanged over the 8 weeks of the study: CD4^+^ T-cell activation -- 6.6% (5.1--9.9) and 6.7% (4.2--12.9) and CD8^+^ T-cell activation -- 20.1% (17.8--27.9) and 20.3% (17.8--29.2). By flow cytometry, duodenal tissue CD4^+^ T-cell percentage increased minimally in six of eight participants with a median increase of 1.2% (not significant) but remained unchanged overall at 15.9% (12.0--26.6) at baseline and 15.5% (13.9--30.2) at week 8. However, by IFA, lamina propria CD3^+^/CD4^+^ lymphocytes (CD4^+^ LPL) increased from 213 cells/mm^2^ (152--243) to 322 cells/mm^2^ (228--433; *P* = 0.016; [Fig. 4](#F4){ref-type="fig"}a). This represented a rise of 139.5 cells/mm^2^ (66.1--216) after 8 weeks of SBI. Whereas the lamina propria CD3^+^/CD8^+^ (CD8^+^ LPL) density was unchanged \[502 cells/mm^2^ (416--650) and 598 cells/mm^2^ (361--699)\] at baseline and week 8, respectively, the lamina propria CD4^+^/CD8^+^ ratio increased from 0.41 (0.23--0.51) to 0.62 (0.34--0.99; *P* = 0.016; [Fig. 4](#F4){ref-type="fig"}b). We previously reported the impact of 9 months of suppressive ART on CD4^+^ LPL density using identical methods wherein an increase from 100.0 cells/mm^2^ (72--145.5) pre-ART to 140.5 cells/mm^2^ (126.7--170.8) at month 9 was measured (*P* = 0.006) [@R16]. This represented an increase of 57 cells/mm^2^ (−9.0, 82) after 9 months of ART, which was significantly less than that observed in the participants receiving 8 weeks of SBI ([Fig. 4](#F4){ref-type="fig"}c). To put these results in perspective, in a cohort of 12 control volunteers of similar demographics and lifestyle who have undergone identical procedures, we have observed CD4^+^ and CD8^+^ LPL densities of 748.8 cells/mm^2^ (510.6--998.5) and 270.8 cells/mm^2^ (226.7, 557.5), respectively [@R16].

![Mucosal immune reconstitution.](aids-27-2207-g004){#F4}

Biomarkers of inflammation, enterocyte damage, and collagen kinetics
--------------------------------------------------------------------

Circulating LPS (irrespective of vacutainer type), IL-1β, IL-6, TNF-α, IFN-γ, IL-12~p70~, IL-4, IL-10, and IL-8 were similar to the levels of controls at baseline and were not changed at the EOT. Results from several parameters were available among those who continued for 48 weeks as described above. MCP-1 was higher in participants at baseline than controls \[476.4 ng/ml (426.4--598.1) versus 336.6 ng/ml (307.9--400.8; *P* = 0.03)\]. MCP-1 levels were unchanged at week 8, but decreased in five of five participants at week 48 \[379.5 ng/ml (225--502) (*P* = 0.06); [Fig. 5](#F5){ref-type="fig"})\].

![Biomarkers of inflammation, enterocyte damage, and collagen kinetics.](aids-27-2207-g005){#F5}

We next examined I-FABP levels in serum. I-FABP reflects enterocyte damage, is elevated in the setting of HIV, and is negatively correlated with survival in recent HIV studies [@R37; @R38]. Unexpectedly, the values initially rose in seven of eight participants after 8 weeks from 3514 pg/ml (2858--4275) to 4042 pg/ml (3233--5613; *P* = 0.039) and then fell below baseline in four of the five who continued receiving SBI to 2442 pg/ml (1267--2875; *P* = 0.12 compared to baseline and 0.06 compared to week 8). Each of these timepoint results is significantly higher in comparison to HIV-negative controls \[21.59 pg/ml (20.0--454.7) (*P* \< 0.0001)\].

Analysis of biomarkers of collagen kinetics provided potential mechanistic explanation for the observed increase in CD4 LPL. Although peripheral blood levels of TGF-β 1, 2, or 3, and hyaluronic acid were not different from those in the controls and did not decline following SBI administration, MMP-9/TIMP-1 ratios in participants were significantly lower than controls at baseline \[0.13 (0.07--0.33) versus 0.42 (0.23--0.44) (*P* = 0.007)\], respectively, and tended to increase at the EOT to 0.33 (0.13--0.73; *P* = 0.08). MMP-2/TIMP-2 levels were not different from those in controls at baseline and did not rise after SBI administration. MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios regulate reabsorption/repair of collagen deposition and have been reported as abnormal in lymph nodes in HIV disease [@R39].

Finally, correlations were sought between lamina propria lymphocyte subset densities and these biomarkers of monocyte activation, enterocyte turnover, and collagen kinetics ([Fig. 5](#F5){ref-type="fig"}). MCP-1 levels were negatively correlated to CD4^+^ LPL (*r* = −0.59, *P* = 0.019) with all time points examined together, suggesting that MCP-1 expression is associated with mucosal immunologic damage. Similarly, MMP-9/TIMP-1 ratios were negatively correlated with CD8^+^ LPL density (*r* = −0.70, *P* = 0.0039) suggesting that factors promoting CD8^+^ T-cell infiltration into the lamina propria correlate with impaired collagen kinetics. Finally, more severe baseline enterocyte damage blunted the magnitude of mucosal immunity recovery as baseline serum I-FABP levels were negatively correlated with subsequent rise in CD4^+^ LPL (*r* = −0.74, *P* = 0.046). These data support the hypothesis that HIV enteropathy presents in a spectrum of severity and that GALT CD4^+^ T-cell recovery is impaired in more severe enterocyte damage.

Discussion
==========

Serum-derived bovine immunoglobulin was serendipitously discovered to reverse severe inflammatory diarrhea in animal husbandry and has been available as a medical food with GRAS FDA (generally regarded as safe -- Food and Drug Administration) status since 2008 [@R40]. Extensive investigations have demonstrated that SBI has broad bacterial and viral antigen neutralizing capacity and reduces intestinal inflammation [@R23; @R25; @R26; @R27; @R41; @R42; @R43; @R44; @R45; @R46]. It has been tested in two clinical trials that confirmed its safety in humans [@R28; @R47]. This pilot, proof-of-concept clinical trial was designed to examine the impact of SBI on HIV enteropathy with the primary focus on gut immunologic and functional parameters. We observed a uniform improvement in stool frequency, consistency, and gastrointestinal related symptoms in all participants over the course of the 8-week intensive study with sustained improvements in those who entered the 48-week extension study. Notably, severe urgency, self-soiling, and nighttime bowel movements, indicative of high water-content stools, resolved during exposure to SBI and returned in a subset of participants during the 4-week 'washout period'. The five participants who opted to continue the extension phase were those who reported return of symptoms (except for one who was subsequently lost to follow-up).

Unexpectedly, we did not observe increased intestinal permeability in this population of virologically suppressed patients. The urine disaccharide assays were performed in the same reference laboratory and methods as employed in the early reports of increased permeability in untreated AIDS patients and those with infectious diarrhea [@R30]. Sharpstone *et al.* reported lactulose/[l]{.smallcaps}-rhamnose mean ratios of 0.03 (SD ± 0.01) in their normal controls and 0.04 (SD ± 0.5) in their asymptomatic AIDS patients, which we reproduced in our cohort 0.03 (0.02), overall. However, they did report abnormal ratios (\>0.05) in their AIDS patients with weight loss and pathogen-negative diarrhea (means of 0.14 and 0.15, respectively), which represent a very different population in the pre-HAART era than our cohort of chronically virologically suppressed patients [@R30]. Increased intestinal permeability is only one reason for increased bacterial translocation. Other conditions, such as bacterial overgrowth syndrome, demonstrate increased bacterial antigen translocation with normal intestinal permeability [@R48]. This report suggests that the mechanisms behind bacterial translocation in HIV patients are due to pathways other than increased macromolecule permeability.

The improved [d]{.smallcaps}-xylose absorption was modest but was observed in seven of eight participants after 7 weeks of SBI. Interestingly, the one participant who did not demonstrate increased absorptive function also did not show an increase in duodenal CD4^+^ T-cell density. Longer observation periods are needed to confirm the improved gut function with SBI administration.

This is the first intervention that demonstrates a substantial increase in duodenal GALT lymphocyte populations in HIV patients. Although the pathologic mechanisms underlying delayed CD4^+^ T-cell immune reconstitution in duodenal lamina propria are unknown, several authors have noted increased collagen staining in both intestinal and lymph node tissue [@R49; @R50; @R51; @R52]. The disrupted architecture may lead to disruption of critical cellular maturational interactions mediated by cytokine homeostasis [@R53]. In addition, an inverse correlation between cross-sectional area of collagen stained and CD4^+^ T-cell stained tissue in the small intestines has been observed [@R50]. The initiating events triggering the profibrotic pathways are believed to be a consequence of HIV infection itself and manifested by a broad range of cytokine-mediated immune activation including IL-6, TGF-β, and hyaluronic acid -- all key contributors to collagen deposition [@R54; @R55; @R56; @R57]. Interestingly, in this cohort of virologically suppressed patients, we did not identify increased systemic levels of any of these or related inflammatory markers, including hsCRP or D-dimer (data not shown) when compared to a cohort of HIV-negative controls. However, the elevated levels of MCP-1 and depressed levels of MMP-9/TIMP-1 ratios describe an environment of monocyte inflammation and migration to the effector site of the lamina propria coupled with abnormal collagen kinetics. Wound repair, collagen deposition, and fibrosis are tightly regulated processes entailing multiple potential pathways with compensatory mechanisms for collagen reabsorption that is primarily performed by the matrix metalloproteinases and modulated by TIMP [@R58; @R59; @R60]. In addition, MCP-1 is one of several important regulators of fibrosis [@R61]. The persistence of abnormal levels of MCP-1 and MMP-9/TIMP-1 has been noted previously in HIV patients [@R39; @R62]. This persistence likely reflects events that are ongoing and uncontrolled in the setting of HIV suppressive therapy. Correlations between MCP-1 and CD4^+^ LPL and between MMP-9/TIMP-1 ratios and CD8^+^ LPL further suggest that these parameters are linked to sustained, uncontrolled antigenic stimulation at the gut mucosal interface. The observation that I-FABP increased in all participants acutely and then fell to below baseline in four of five participants suggests a biological explanation for the clinical improvements and increased absorption function. I-FABP is a marker for enterocyte damage that has been validated in coeliac disease response to a gluten-free diet. It is also related to repair and proliferation among other important cellular pathways [@R63; @R64]. The initial increase may reflect enterocyte repair and turnover following neutralization of damaging inflammatory bacterial antigen by SBI. The strong correlation between baseline I-FABP levels and subsequent recovery in CD4^+^ LPL following SBI administration is consistent with the hypothesis that neutralization of bacterial antigen promotes improved clinical, functional, and immunologic composition of the duodenal mucosal compartment. The absence of circulating CD4^+^ T-cell count increases likely reflects the complex architectural and functional abnormalities that will require a longer duration of treatment and observation to reverse. Longer duration studies are planned to test this hypothesis.

NexGen sequencing analysis of the gut microbiota is ongoing to demonstrate the impact of SBI on gut microbiota as well as gastrointestinal functional and immunologic parameters. Sustained reversal of ongoing profibrotic pathways and interruption of collagen repair in the setting of HIV disease are needed to restore the mucosal immune system to preinfection levels.
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